CTLA4 and colitis: Relapse of colitis occurred in 4/23 rechallenged patients (17.4%) after a median time of 9.5 weeks (IQR 7.5–27.5 weeks) including the only patient treated with anti-PD1 + anti-CTLA-4 upon rechallenge.